J
J. Almond
Researcher at University of Liverpool
Publications - 6
Citations - 1620
J. Almond is an academic researcher from University of Liverpool. The author has contributed to research in topics: Pancreatic cancer & Survival rate. The author has an hindex of 4, co-authored 6 publications receiving 1526 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
John P. Neoptolemos,Janet A. Dunn,Deborah D. Stocken,J. Almond,Karl-Heinrich Link,H. G. Beger,Claudio Bassi,Massimo Falconi,Paolo Pederzoli,Christos Dervenis,Laureano Fernández-Cruz,François Lacaine,Akos F. Pap,David Spooner,David J. Kerr,Helmut Friess,Markus W. Büchler +16 more
TL;DR: This study showed no survival benefit for chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy, justifying further randomised controlled trials of adjUvant chemotherapy in pancreatic cancer.
Journal ArticleDOI
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
John P. Neoptolemos,Deborah D. Stocken,Janet A. Dunn,J. Almond,Hans G. Beger,Paolo Pederzoli,Claudio Bassi,Christos Dervenis,Laureano Fernández-Cruz,François Lacaine,John A. C. Buckels,M. Deakin,Fawzi Adab,Robert Sutton,Clem W. Imrie,Ingemar Ihse,Tibor Tihanyi,Attila Oláh,Sergio Pedrazzoli,David Spooner,David J. Kerr,Helmut Friess,Markus W. Büchler +22 more
TL;DR: Resection margin-positive pancreatic tumors represent a biologically more aggressive cancer; these patients benefit from resection and adjuvant chemotherapy but not chemoradiation; the magnitude of benefit for chemotherapy treatment is reduced for patients with R1 margins versus those with R0 margins.
Journal ArticleDOI
European Study Group for Pancreatic Cancer‐1 interim results: a European randomized study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer
John P. Neoptolemos,Janet A. Dunn,D.D. Moffitt,J. Almond,Karl-Heinrich Link,H. G. Beger,Claudio Bassi,Paolo Pederzoli,C. Dervenis,Laureano Fernández-Cruz,François Lacaine,David Spooner,David J. Kerr,Helmut Friess,M.W. Büchler +14 more
TL;DR: The aims of the study were to answer whether there is a role for chemoradiation and 5‐fluorouracil (5‐FU–folinic acid (FA) weekly and whether there are plans for chemotherapy weekly.
Journal ArticleDOI
ESPAC-1: A European, randomised study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer
John P. Neoptolemos,D.D. Moffitt,Janet A. Dunn,J. Almond,H. G. Beger,Karl-Heinrich Link,Paolo Pederzoli,Claudio Bassi,C. Dervernis,L. Fernandez-Cruz,François Lacaine,David Spooner,David J. Kerr,H. Freiss,M.W. Büchler +14 more
Journal ArticleDOI
Survival and quality of life (QoL) of patients in ESPAC-1: A european, randomised study of assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer
John P. Neoptolemos,D.D. Moffitt,J.A. Dunn,J. Almond,H. G. Beger,Claudio Bassi,C. Dervernis,L. Femandez-Cruz,François Lacaine,David Spooner,David J. Kerr,M.W. Büchler +11 more